{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:28:25Z","timestamp":1794288505781,"version":"4.9.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00740-4","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:47:20Z","timestamp":1772444840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrative bioinformatics approach to the mRNA vaccine development for the human papillomavirus using the capsid protein"],"prefix":"10.1186","volume":"21","author":[{"given":"Shan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akmal","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Yaqoob","family":"Shahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Afghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"6","key":"740_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","volume":"9","author":"MH Einstein","year":"2009","unstructured":"Einstein MH, et al. Clinician\u2019s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9(6):347\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"740_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","volume":"7","author":"S De Sanjos\u00e9","year":"2007","unstructured":"De Sanjos\u00e9 S, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453\u20139.","journal-title":"Lancet Infect Dis"},{"key":"740_CR3","unstructured":"van Eer K. The human papillomavirus: dynamics between vaccination, viral properties and surveillance. 2025."},{"issue":"1","key":"740_CR4","doi-asserted-by":"publisher","first-page":"e0313559","DOI":"10.1371\/journal.pone.0313559","volume":"20","author":"MM Rahman","year":"2025","unstructured":"Rahman MM, et al. Designing of an mRNA vaccine against high-risk human papillomavirus targeting the E6 and E7 oncoproteins exploiting immunoinformatics and dynamic simulation. PLoS ONE. 2025;20(1):e0313559.","journal-title":"PLoS ONE"},{"key":"740_CR5","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","volume":"30","author":"J Doorbar","year":"2012","unstructured":"Doorbar J, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30:F55\u201370.","journal-title":"Vaccine"},{"issue":"7","key":"740_CR6","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3390\/v7072802","volume":"7","author":"N Egawa","year":"2015","unstructured":"Egawa N, et al. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015;7(7):3863\u201390.","journal-title":"Viruses"},{"issue":"1","key":"740_CR7","doi-asserted-by":"publisher","first-page":"15402","DOI":"10.1038\/s41598-025-96667-3","volume":"15","author":"SK Mishra","year":"2025","unstructured":"Mishra SK, et al. Computational analysis of Lupenone derivatives as potential inhibitor of human papillomavirus oncoprotein E6 associated cervical cancer. Sci Rep. 2025;15(1):15402.","journal-title":"Sci Rep"},{"issue":"2","key":"740_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.yexmp.2014.08.004","volume":"97","author":"J Munkhdelger","year":"2014","unstructured":"Munkhdelger J, et al. Performance of HPV E6\/E7 mRNA RT-qPCR for screening and diagnosis of cervical cancer with ThinPrep\u00ae pap test samples. Exp Mol Pathol. 2014;97(2):279\u201384.","journal-title":"Exp Mol Pathol"},{"issue":"21","key":"740_CR9","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1002\/cncr.33795","volume":"127","author":"S Lin","year":"2021","unstructured":"Lin S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127(21):4030\u20139.","journal-title":"Cancer"},{"issue":"3","key":"740_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1470-2045(19)30072-5","volume":"20","author":"M Brisson","year":"2019","unstructured":"Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20(3):319\u201321.","journal-title":"Lancet Oncol"},{"issue":"2","key":"740_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/088282403322017866","volume":"16","author":"GL Eiben","year":"2003","unstructured":"Eiben GL, et al. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003;16(2):111\u201321.","journal-title":"Viral Immunol"},{"issue":"2","key":"740_CR12","first-page":"80","volume":"40","author":"P Brianti","year":"2017","unstructured":"Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80\u20135.","journal-title":"New Microbiol"},{"key":"740_CR13","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.ijgo.2015.02.009","volume":"131","author":"L Denny","year":"2015","unstructured":"Denny L, Prendiville W. Cancer of the cervix: early detection and cost-effective solutions. Int J Gynecol Obstet. 2015;131:S28\u201332.","journal-title":"Int J Gynecol Obstet"},{"issue":"10071","key":"740_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0140-6736(16)31795-0","volume":"389","author":"L Denny","year":"2017","unstructured":"Denny L, et al. Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet. 2017;389(10071):861\u201370.","journal-title":"Lancet"},{"issue":"1","key":"740_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1750-9378-2-6","volume":"2","author":"F Sitas","year":"2007","unstructured":"Sitas F, et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agents Cancer. 2007;2(1):6.","journal-title":"Infect Agents Cancer"},{"issue":"3","key":"740_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/ijc.34269","volume":"152","author":"AA Deshmukh","year":"2023","unstructured":"Deshmukh AA, et al. Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: a worldwide analysis. Int J Cancer. 2023;152(3):417\u201328.","journal-title":"Int J Cancer"},{"issue":"1\u20132","key":"740_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.virol.2013.06.007","volume":"445","author":"HA Cubie","year":"2013","unstructured":"Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445(1\u20132):21\u201334.","journal-title":"Virology"},{"issue":"2","key":"740_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1128\/JVI.72.2.1131-1137.1998","volume":"72","author":"JT Thomas","year":"1998","unstructured":"Thomas JT, Laimins LA. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J Virol. 1998;72(2):1131\u20137.","journal-title":"J Virol"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev.mi.48.100194.002235","volume":"48","author":"H Zur Hausen","year":"1994","unstructured":"Zur Hausen H, De Villiers E-M. Human papillomaviruses. Annu Rev Microbiol. 1994;48:427\u201348.","journal-title":"Annu Rev Microbiol"},{"key":"740_CR20","first-page":"1","volume":"64","author":"KH Vousden","year":"1994","unstructured":"Vousden KH. Interactions between papillomavirus proteins and tumor suppressor gene products. Adv Cancer Res. 1994;64:1\u201324.","journal-title":"Adv Cancer Res"},{"issue":"5","key":"740_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/ijc.2910510527","volume":"51","author":"K von Doeberitz","year":"1992","unstructured":"von Doeberitz K. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti\u2010sense RNA. Int J Cancer. 1992;51(5):831\u20134.","journal-title":"Int J Cancer"},{"issue":"12","key":"740_CR22","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1002\/j.1460-2075.1989.tb08570.x","volume":"8","author":"P Hawley-Nelson","year":"1989","unstructured":"Hawley-Nelson P, et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989;8(12):3905\u201310.","journal-title":"EMBO J"},{"issue":"6","key":"740_CR23","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","volume":"63","author":"M Scheffner","year":"1990","unstructured":"Scheffner M, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129\u201336.","journal-title":"Cell"},{"issue":"4893","key":"740_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.2537532","volume":"243","author":"N Dyson","year":"1989","unstructured":"Dyson N, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934\u20137.","journal-title":"Science"},{"key":"740_CR25","first-page":"81","volume":"2","author":"DA Dobrovolskaya","year":"2025","unstructured":"Dobrovolskaya DA, et al. The role of L\u2081 and L\u2082 capsid proteins of human papillomavirus in the differential diagnosis of squamous intraepithelial lesions. Obstet Gynecol. 2025;2:81\u201390.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"740_CR26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/v15071440","volume":"15","author":"A-L Williamson","year":"2023","unstructured":"Williamson A-L. Recent developments in human papillomavirus (HPV) vaccinology. Viruses. 2023;15(7):1440.","journal-title":"Viruses"},{"issue":"4","key":"740_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, et al. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discovery. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"740_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/gt.2017.5","volume":"24","author":"S Guan","year":"2017","unstructured":"Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017;24(3):133\u201343.","journal-title":"Gene Ther"},{"issue":"11","key":"740_CR29","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, et al. Incorporation of Pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833\u201340.","journal-title":"Mol Ther"},{"issue":"9","key":"740_CR30","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess A, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015;23(9):1456\u201364.","journal-title":"Mol Ther"},{"key":"740_CR31","doi-asserted-by":"crossref","unstructured":"Rani NA, et al. Development of multi-epitope subunit vaccines against emerging carp viruses cyprinid herpesvirus 1 and 3 using immunoinformatics approach. Sci Rep. 2024;14(1):11783.","DOI":"10.1038\/s41598-024-61074-7"},{"issue":"20","key":"740_CR32","doi-asserted-by":"publisher","first-page":"10617","DOI":"10.1080\/07391102.2023.2258403","volume":"42","author":"S Ahmad","year":"2024","unstructured":"Ahmad S, et al. Computational design of a multi-epitope vaccine candidate against Langya henipavirus using surface proteins. J Biomol Struct Dynamics. 2024;42(20):10617\u201334.","journal-title":"J Biomol Struct Dynamics"},{"key":"740_CR33","doi-asserted-by":"crossref","unstructured":"Rawat SS, Sharma A, Khatri M, et al. Immunoinformatics approaches for vaccine design: a fast and secure strategy for successful vaccine development. MDPI. 2023;221.","DOI":"10.3390\/vaccines11020221"},{"issue":"9","key":"740_CR34","doi-asserted-by":"publisher","first-page":"e0310398","DOI":"10.1371\/journal.pone.0310398","volume":"19","author":"R Parvin","year":"2024","unstructured":"Parvin R, et al. Designing of a chimeric multiepitope vaccine against Bancroftian lymphatic filariasis through immunoinformatics approaches. PLoS ONE. 2024;19(9):e0310398.","journal-title":"PLoS ONE"},{"issue":"3","key":"740_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1573409919666230612125440","volume":"20","author":"I Farhani","year":"2024","unstructured":"Farhani I, et al. Designing a Multi-epitope vaccine against the SARS-CoV-2 variant based on an immunoinformatics approach. Curr Comput-Aided Drug Design. 2024;20(3):274\u201390.","journal-title":"Curr Comput-Aided Drug Design"},{"key":"740_CR36","doi-asserted-by":"crossref","unstructured":"Oli AN, et al. Immunoinformatics and vaccine development: an overview. Immuno Targets Ther. 2020;13:13\u2013","DOI":"10.2147\/ITT.S241064"},{"key":"740_CR37","doi-asserted-by":"publisher","first-page":"127883","DOI":"10.1016\/j.molliq.2025.127883","volume":"433","author":"SK Mishra","year":"2025","unstructured":"Mishra SK, et al. Integrated immunoinformatics and reverse vaccinology assisted novel multi-epitope vaccine against coxsackievirus A10 investigating its whole genome encoded polyprotein. J Mol Liq. 2025;433:127883.","journal-title":"J Mol Liq"},{"key":"740_CR38","doi-asserted-by":"crossref","unstructured":"Kumar Mishra S, et al. An integrated mutation-based immunoinformatic approach incorporating variability in epitopes: a study based on HIV subtype C. Front Immunol. 2025;16:2025.","DOI":"10.3389\/fimmu.2025.1540253"},{"key":"740_CR39","doi-asserted-by":"crossref","unstructured":"Sippl MJ. Recognition of errors in three-dimensional structures of proteins. Proteins: Struct Funct Bioinformatics. 1993;17(4):355\u2013362.","DOI":"10.1002\/prot.340170404"},{"issue":"D1","key":"740_CR40","doi-asserted-by":"publisher","first-page":"D10","DOI":"10.1093\/nar\/gkaa892","volume":"49","author":"EW Sayers","year":"2021","unstructured":"Sayers EW, et al. Database resources of the National center for biotechnology information. Nucleic Acids Res. 2021;49(D1):D10\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"740_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2105-8-4","volume":"8","author":"IA Doytchinova","year":"2007","unstructured":"Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8(1):4.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"740_CR42","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/1471-2105-8-424","volume":"8","author":"MV Larsen","year":"2007","unstructured":"Larsen MV, et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 2007;8(1):424.","journal-title":"BMC Bioinformatics"},{"issue":"W1","key":"740_CR43","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson B, et al. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif Deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449\u201354.","journal-title":"Nucleic Acids Res"},{"key":"740_CR44","doi-asserted-by":"publisher","first-page":"102215","DOI":"10.1016\/j.coi.2022.102215","volume":"77","author":"JJ Baljon","year":"2022","unstructured":"Baljon JJ, Wilson JT. Bioinspired vaccines to enhance MHC class-I antigen cross-presentation. Curr Opin Immunol. 2022;77:102215.","journal-title":"Curr Opin Immunol"},{"issue":"D1","key":"740_CR45","doi-asserted-by":"publisher","first-page":"D339","DOI":"10.1093\/nar\/gky1006","volume":"47","author":"R Vita","year":"2019","unstructured":"Vita R, et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1):D339\u201343.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"740_CR46","first-page":"2680160","volume":"2017","author":"JL Sanchez-Trincado","year":"2017","unstructured":"Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T-and B\u2010cell epitope prediction. J Immunol Res. 2017;2017(1):2680160.","journal-title":"J Immunol Res"},{"key":"740_CR47","doi-asserted-by":"crossref","unstructured":"Oladipo EK, et al. Immunoinformatics-based strategies for mRNA vaccine development against Ilesha virus. In Silico Res Biomed. 2025;100046.","DOI":"10.1016\/j.insi.2025.100046"},{"issue":"7","key":"740_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/computation10070117","volume":"10","author":"OO Oluwagbemi","year":"2022","unstructured":"Oluwagbemi OO, et al. Bioinformatics, computational informatics, and modeling approaches to the design of mRNA COVID-19 vaccine candidates. Computation. 2022;10(7):117.","journal-title":"Computation"},{"issue":"20","key":"740_CR49","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.1073\/pnas.89.20.9612","volume":"89","author":"F Lejbkowicz","year":"1992","unstructured":"Lejbkowicz F, et al. A fraction of the mRNA 5\u2019cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus. Proc Natl Acad Sci. 1992;89(20):9612\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"740_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/14760584.2021.1991794","volume":"21","author":"D Mekonnen","year":"2022","unstructured":"Mekonnen D, Mengist HM, Jin T. SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways. Expert Rev Vaccines. 2022;21(1):69\u201381.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"740_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12865-024-00668-2","volume":"25","author":"EK Oladipo","year":"2024","unstructured":"Oladipo EK, et al. Bioinformatics designing of an mRNA vaccine for Mokola virus (MOKV) using immunoinformatics as a secure strategy for successful vaccine development. BMC Immunol. 2024;25(1):77.","journal-title":"BMC Immunol"},{"issue":"6","key":"740_CR52","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1007\/s00894-014-2278-5","volume":"20","author":"I Dimitrov","year":"2014","unstructured":"Dimitrov I, et al. AllerTOP v. 2\u2014a server for in Silico prediction of allergens. J Mol Model. 2014;20(6):2278.","journal-title":"J Mol Model"},{"key":"740_CR53","doi-asserted-by":"crossref","unstructured":"Sharma N, et al. ToxinPred2: an improved method for predicting toxicity of proteins. Brief Bioinform. 2022;23(5):bbac316.","DOI":"10.1093\/bib\/bbac174"},{"key":"740_CR54","doi-asserted-by":"crossref","unstructured":"Gasteiger E, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. Proteomics protocols handbook. Springer; 2005. p. 571\u2013607.","DOI":"10.1385\/1-59259-890-0:571"},{"issue":"19","key":"740_CR55","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1093\/bioinformatics\/btx345","volume":"33","author":"M Hebditch","year":"2017","unstructured":"Hebditch M, et al. Protein\u2013Sol: a web tool for predicting protein solubility from sequence. Bioinformatics. 2017;33(19):3098\u2013100.","journal-title":"Bioinformatics"},{"issue":"10","key":"740_CR56","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/s41596-022-00728-0","volume":"17","author":"X Zhou","year":"2022","unstructured":"Zhou X, et al. I-TASSER-MTD: a deep-learning-based platform for multi-domain protein structure and function prediction. Nat Protoc. 2022;17(10):2326\u201353.","journal-title":"Nat Protoc"},{"issue":"Database issue","key":"740_CR57","doi-asserted-by":"publisher","first-page":"D292","DOI":"10.1093\/nar\/gkt940","volume":"42","author":"TA de Beer","year":"2014","unstructured":"de Beer TA, et al. PDBsum additions. Nucleic Acids Res. 2014;42(Database issue):D292\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"740_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1107\/S0021889892009944","volume":"26","author":"RA Laskowski","year":"1993","unstructured":"Laskowski RA, et al. PROCHECK: a program to check the stereochemical quality of protein structures. Appl Crystallogr. 1993;26(2):283\u201391.","journal-title":"Appl Crystallogr"},{"key":"740_CR59","doi-asserted-by":"crossref","unstructured":"Ko J, et al. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 2012;40(Web Server issue):W294\u20137.","DOI":"10.1093\/nar\/gks493"},{"issue":"1","key":"740_CR60","doi-asserted-by":"publisher","first-page":"1157023","DOI":"10.1155\/2021\/1157023","volume":"2021","author":"AS Sameer","year":"2021","unstructured":"Sameer AS, Nissar S. Toll-like receptors (TLRs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. Biomed Res Int. 2021;2021(1):1157023.","journal-title":"Biomed Res Int"},{"issue":"2","key":"740_CR61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nprot.2016.169","volume":"12","author":"D Kozakov","year":"2017","unstructured":"Kozakov D, et al. The cluspro web server for protein\u2013protein Docking. Nat Protoc. 2017;12(2):255\u201378.","journal-title":"Nat Protoc"},{"issue":"W1","key":"740_CR62","doi-asserted-by":"publisher","first-page":"W271","DOI":"10.1093\/nar\/gku339","volume":"42","author":"JR L\u00f3pez-Blanco","year":"2014","unstructured":"L\u00f3pez-Blanco JR, et al. iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res. 2014;42(W1):W271\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"740_CR63","doi-asserted-by":"publisher","first-page":"e9862","DOI":"10.1371\/journal.pone.0009862","volume":"5","author":"N Rapin","year":"2010","unstructured":"Rapin N, et al. Computational immunology Meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS ONE. 2010;5(4):e9862.","journal-title":"PLoS ONE"},{"issue":"Web Server issu","key":"740_CR64","doi-asserted-by":"publisher","first-page":"W526","DOI":"10.1093\/nar\/gki376","volume":"33","author":"A Grote","year":"2005","unstructured":"Grote A, et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005;33(Web Server issue):W526\u201331.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"740_CR65","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1038\/s41598-017-09199-w","volume":"7","author":"M Ali","year":"2017","unstructured":"Ali M, et al. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci Rep. 2017;7(1):9232.","journal-title":"Sci Rep"},{"issue":"1","key":"740_CR66","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41598-020-80899-6","volume":"11","author":"S Bibi","year":"2021","unstructured":"Bibi S, et al. In Silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology. Sci Rep. 2021;11(1):1249.","journal-title":"Sci Rep"},{"issue":"suppl2","key":"740_CR67","doi-asserted-by":"publisher","first-page":"W70","DOI":"10.1093\/nar\/gkn188","volume":"36","author":"AR Gruber","year":"2008","unstructured":"Gruber AR, et al. The Vienna RNA websuite. Nucleic Acids Res. 2008;36(suppl2):W70\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"740_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1748-7188-6-26","volume":"6","author":"R Lorenz","year":"2011","unstructured":"Lorenz R, et al. ViennaRNA package 2.0. Algorithms Mol Biology. 2011;6(1):26.","journal-title":"Algorithms Mol Biology"},{"issue":"7","key":"740_CR69","doi-asserted-by":"publisher","first-page":"e0275237","DOI":"10.1371\/journal.pone.0275237","volume":"18","author":"H Motamedi","year":"2023","unstructured":"Motamedi H, et al. In Silico designing and immunoinformatics analysis of a novel peptide vaccine against metallo-beta-lactamase (VIM and IMP) variants. PLoS ONE. 2023;18(7):e0275237.","journal-title":"PLoS ONE"},{"key":"740_CR70","doi-asserted-by":"publisher","first-page":"106635","DOI":"10.1016\/j.fitote.2025.106635","volume":"184","author":"MA Mbock","year":"2025","unstructured":"Mbock MA, et al. Safety assessment of Detarium microcarpum Guil. & Perr. (Leguminosae) root bark extract in rats: Acute, sub-acute toxicity, ADMET, molecular docking, and molecular dynamics simulations approach. Fitoterapia. 2025;184:106635.","journal-title":"Fitoterapia"},{"issue":"2","key":"740_CR71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s40203-024-00278-1","volume":"12","author":"KA Oluwafemi","year":"2024","unstructured":"Oluwafemi KA, et al. Investigating the effect of 1,2-Dibenzoylhydrazine on Staphylococcus aureus using integrated computational approaches. Silico Pharmacol. 2024;12(2):102.","journal-title":"Silico Pharmacol"},{"issue":"1","key":"740_CR72","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1038\/s41598-024-84401-4","volume":"15","author":"B Othman","year":"2025","unstructured":"Othman B, et al. Comprehensive Pharmacokinetic profiling and molecular Docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer. Sci Rep. 2025;15(1):5426.","journal-title":"Sci Rep"},{"issue":"8","key":"740_CR73","doi-asserted-by":"publisher","first-page":"e0290576","DOI":"10.1371\/journal.pone.0290576","volume":"18","author":"S Ullah","year":"2023","unstructured":"Ullah S, et al. A computational approach to fighting type 1 diabetes by targeting 2\u00a0C Coxsackie B virus protein with flavonoids. PLoS ONE. 2023;18(8):e0290576.","journal-title":"PLoS ONE"},{"issue":"9","key":"740_CR74","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.sjbs.2023.103753","volume":"30","author":"ZK Bagewadi","year":"2023","unstructured":"Bagewadi ZK, et al. Molecular dynamics and simulation analysis against superoxide dismutase (SOD) target of micrococcus luteus with secondary metabolites from Bacillus licheniformis recognized by genome mining approach. Saudi J Biol Sci. 2023;30(9):103753.","journal-title":"Saudi J Biol Sci"},{"issue":"31","key":"740_CR75","doi-asserted-by":"publisher","first-page":"22209","DOI":"10.1039\/D4RA02540G","volume":"14","author":"Y Chemam","year":"2024","unstructured":"Chemam Y, et al. Phytochemical on-line screening and in Silico study of Helianthemum confertum: antioxidant activity, DFT, MD simulation, ADME\/T analysis, and Xanthine oxidase binding. RSC Adv. 2024;14(31):22209\u201328.","journal-title":"RSC Adv"},{"key":"740_CR76","doi-asserted-by":"publisher","first-page":"124091","DOI":"10.1016\/j.ijheatmasstransfer.2023.124091","volume":"208","author":"H Sun","year":"2023","unstructured":"Sun H, et al. Molecular dynamics study on the role of hydrogen bonds and interfacial heat transfer between diverse silica surfaces and organic liquids. Int J Heat Mass Transf. 2023;208:124091.","journal-title":"Int J Heat Mass Transf"},{"key":"740_CR77","unstructured":"David CC, Jacobs DJ, Livesay DR. Humana: Totowa, NJ; 2014. p. 193\u2013226."},{"issue":"5","key":"740_CR78","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449\u201361.","journal-title":"Expert Opin Drug Discov"},{"issue":"9518","key":"740_CR79","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper DM, et al. Sustained efficacy up to 4\u00b7 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247\u201355.","journal-title":"Lancet"},{"issue":"9447","key":"740_CR80","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"DM Harper","year":"2004","unstructured":"Harper DM, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757\u201365.","journal-title":"Lancet"},{"issue":"9580","key":"740_CR81","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen J, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161\u201370.","journal-title":"Lancet"},{"issue":"19","key":"740_CR82","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"740_CR83","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","volume":"6","author":"LL Villa","year":"2005","unstructured":"Villa LL, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271\u20138.","journal-title":"Lancet Oncol"},{"issue":"1","key":"740_CR84","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","volume":"154","author":"AR Giuliano","year":"2019","unstructured":"Giuliano AR, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019;154(1):110\u20137.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"740_CR85","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"740_CR86","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/QAI.0000000000001113","volume":"73","author":"GM Clifford","year":"2016","unstructured":"Clifford GM, et al. Effect of HIV infection on human papillomavirus types causing invasive cervical cancer in Africa. JAIDS J Acquir Immune Defic Syndr. 2016;73(3):332\u20139.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"740_CR87","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/1471-2407-13-553","volume":"13","author":"JM Pimenta","year":"2013","unstructured":"Pimenta JM, et al. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer. 2013;13(1):553.","journal-title":"BMC Cancer"},{"key":"740_CR88","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bpobgyn.2017.09.008","volume":"47","author":"G Hancock","year":"2018","unstructured":"Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynecol. 2018;47:59\u201372.","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"key":"740_CR89","first-page":"107327482412386","volume-title":"Advancements in mRNA vaccines: a promising approach for combating human Papillomavirus-related cancers","author":"L Iqbal","year":"2024","unstructured":"Iqbal L, Jehan M, Azam S. Advancements in mRNA vaccines: a promising approach for combating human Papillomavirus-related cancers. Los Angeles, CA: SAGE Publications Sage CA; 2024. p. 10732748241238629."},{"issue":"3","key":"740_CR90","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s12026-022-09351-3","volume":"71","author":"Y Mohammadi","year":"2023","unstructured":"Mohammadi Y, et al. In Silico design and evaluation of a novel mRNA vaccine against BK virus: a reverse vaccinology approach. Immunol Res. 2023;71(3):422\u201341.","journal-title":"Immunol Res"},{"issue":"7","key":"740_CR91","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13205-024-04022-6","volume":"14","author":"A Roy","year":"2024","unstructured":"Roy A, et al. Integrating pan-genome and reverse vaccinology to design multi-epitope vaccine against herpes simplex virus type-1. 3 Biotech. 2024;14(7):176.","journal-title":"3 Biotech"},{"key":"740_CR92","doi-asserted-by":"publisher","first-page":"101782","DOI":"10.1016\/j.biologicals.2024.101782","volume":"87","author":"R Biswas","year":"2024","unstructured":"Biswas R, et al. Designing multi-epitope vaccine against human cytomegalovirus integrating pan-genome and reverse vaccinology pipelines. Biologicals. 2024;87:101782.","journal-title":"Biologicals"},{"issue":"4","key":"740_CR93","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14737159.2022.2065194","volume":"22","author":"E Behboudi","year":"2022","unstructured":"Behboudi E, et al. Transcription activator-like effector nuclease (TALEN) as a promising diagnostic approach for COVID-19. Expert Rev Mol Diagn. 2022;22(4):395\u20137.","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"740_CR94","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/life12081254","volume":"12","author":"J Nitika","year":"2022","unstructured":"Nitika J, Wei, Hui A-M. The delivery of mRNA vaccines for therapeutics. Life. 2022;12(8):1254.","journal-title":"Life"},{"key":"740_CR95","doi-asserted-by":"crossref","unstructured":"Biswas R, Anbarasu A. Identification of novel zinc-binding inhibitors against key microbial metallohydrolase DapE in Klebsiella pneumoniae: an integrated ligand-based virtual screening, molecular docking, molecular dynamics, and MM\/PBSA approach. Integr Biol (Camb). 2025;17.","DOI":"10.1093\/intbio\/zyaf018"},{"key":"740_CR96","doi-asserted-by":"publisher","first-page":"1213285","DOI":"10.3389\/fimmu.2023.1213285","volume":"14","author":"K Zhou","year":"2023","unstructured":"Zhou K, et al. HPV16 E6\/E7-based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions. Front Immunol. 2023;14:1213285.","journal-title":"Front Immunol"},{"issue":"1","key":"740_CR97","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1038\/s41598-017-08842-w","volume":"7","author":"N Khatoon","year":"2017","unstructured":"Khatoon N, Pandey RK, Prajapati VK. Exploring leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. Sci Rep. 2017;7(1):8285.","journal-title":"Sci Rep"},{"issue":"5","key":"740_CR98","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","volume":"16","author":"S Scheiblhofer","year":"2017","unstructured":"Scheiblhofer S, et al. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Expert Rev Vaccines. 2017;16(5):479\u201389.","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"740_CR99","first-page":"1351","volume":"12","author":"SK Masenga","year":"2023","unstructured":"Masenga SK, et al. HIV\u2013host Cell Interact Cells. 2023;12(10):1351.","journal-title":"HIV\u2013host Cell Interact Cells"},{"issue":"5","key":"740_CR100","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41435-022-00175-7","volume":"23","author":"L-Y Lin","year":"2022","unstructured":"Lin L-Y, et al. Fc receptors and the diversity of antibody responses to HIV infection and vaccination. Genes Immun. 2022;23(5):149\u201356.","journal-title":"Genes Immun"},{"issue":"10","key":"740_CR101","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1128\/JVI.77.10.5889-5901.2003","volume":"77","author":"R Pantophlet","year":"2003","unstructured":"Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol. 2003;77(10):5889\u2013901.","journal-title":"J Virol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00740-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00740-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00740-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:03:48Z","timestamp":1775574228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00740-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00740-4","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study excludes any human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human research"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}